Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.
Dr Alison Birtle (Rosemere Cancer Centre, Royal Preston Hospital, UK) discusses the rationale for adjuvant chemotherapy for upper tract urothelial cancer (UTUC), the POUT trial and its practice-changing implications for treatment of UTUC.
A themed content collection to help HCPs keep up to date with the latest developments in the area of CNS metastases arising from non-small-cell lung cancer, as well as consolidate knowledge of the risk factors and treatment options.
This collection was made possible by educational funding provided by AstraZeneca.
Patients with nonsquamous non-small-cell lung cancer who have sensitizing EGFR mutations or liver metastases may benefit from the addition of atezolizumab to bevacizumab and chemotherapy, IMpower150 trial data show.
Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.
The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.
Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.
A third of cancer patients and survivors use complementary and alternative medicine, but they do not always disclose its use to their physicians, findings indicate.
Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.
This program was made possible thanks to an independent educational grant from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
